Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19

NCT04776044 is registered in ClinicalTrials.gov with Atriva Therapeutics GmbH as lead sponsor.

NCT NCT04776044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
Lead sponsor
Atriva Therapeutics GmbH
Phase
Phase 2
Overall status
Terminated
Start date
April 12, 2021
Completion date
August 9, 2022
Enrollment
133 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19